A Research Guide for
Breast Cancer

When most people first hear “breast cancer,” they assume the stage — the number from I to IV — is what matters most. The stage does matter, but in modern breast cancer the subtype often matters even more, because it determines which treatments can actually work against your specific cancer. Two women with the same-size tumor and the same number of involved lymph nodes can receive completely different treatments, and have quite different outlooks, simply because their cancers are different biological diseases.

This is why the receptor results from your biopsy — ER, PR, and HER2 — are the most important piece of information in your chart. They sort breast cancer into groups that respond to entirely different therapies: hormone-blocking pills for hormone-receptor-positive disease, HER2-targeted antibodies and antibody-drug conjugates for HER2-positive disease, and immunotherapy plus (for some) PARP-inhibitor pills for triple-negative disease. A treatment that is life-saving for one subtype does nothing for another, which is why there is no single “breast cancer treatment” — there are several, matched to the biology.

A few practical takeaways follow. It is completely reasonable to ask your team directly: “What is my subtype, and what does it mean for my options?” It is worth making sure the receptor testing is complete and, if anything seems borderline or surprising, confirmed — because the whole plan flows from it. And if your cancer ever returns or spreads, the subtype can sometimes change, so a repeat biopsy may be recommended to make sure the treatment still matches the cancer.

It also helps to know that the subtypes differ in how common and how studied they are. Hormone-receptor-positive disease accounts for roughly seventy percent of cases and is the most treatable on average but asks for the longest commitment to therapy; triple-negative disease is less common and more aggressive but has seen some of the fastest recent progress with immunotherapy and antibody-drug conjugates; and HER2-positive disease, once among the most feared, is now one of the most effectively targeted. Wherever your cancer falls, the past decade has added meaningful options — so a subtype that sounded discouraging even a few years ago may now have treatments that did not exist then.

Hormone receptor-positive, HER2-negative breast cancer is the most common subtype. These tumors are fueled by estrogen and/or progesterone. They tend to grow more slowly than other subtypes and have the best overall prognosis.

Treatment backbone: Endocrine (hormone-blocking) therapy is the foundation — tamoxifen for premenopausal women, aromatase inhibitors (letrozole, anastrozole, exemestane) for postmenopausal women. Chemotherapy may or may not be needed, guided by genomic assays (Oncotype DX, MammaPrint). CDK4/6 inhibitors are a cornerstone of treatment: ribociclib and abemaciclib are approved to lower recurrence risk in high-risk early-stage disease, and all three (ribociclib, abemaciclib, palbociclib) are used in the metastatic setting.

Key consideration: While HR+ cancers have the best initial prognosis, they carry a sustained risk of late recurrence (beyond five years after diagnosis), which is why extended endocrine therapy is often recommended.

HER2-positive breast cancers overexpress the HER2 protein, which drives aggressive growth. Before the development of HER2-targeted therapies, these cancers had a poor prognosis. Today, HER2+ breast cancer is one of the most treatable subtypes thanks to a growing arsenal of targeted drugs.

Treatment backbone: Trastuzumab (Herceptin) is the foundation, typically combined with pertuzumab and chemotherapy. Neoadjuvant (pre-surgery) treatment is standard for most HER2+ cancers. If cancer remains after neoadjuvant therapy, ado-trastuzumab emtansine (T-DM1, Kadcyla) replaces trastuzumab in the adjuvant setting (KATHERINE trial). Trastuzumab deruxtecan (T-DXd, Enhertu) has transformed treatment of metastatic HER2+ disease.

New in early-stage HER2+ disease (2026): In May 2026 the FDA approved trastuzumab deruxtecan (T-DXd, Enhertu) for HER2-positive early-stage breast cancer in two settings: as neoadjuvant treatment of Stage II or III disease (followed by taxane, trastuzumab, and pertuzumab — THP; DESTINY-Breast11, NCT05113251), and as adjuvant treatment for patients with residual invasive disease after neoadjuvant therapy (DESTINY-Breast05, NCT04622319, where T-DXd improved invasive disease-free survival versus T-DM1). This gives some patients a more effective option than T-DM1 after surgery — ask your oncologist whether it applies to your case.

Key consideration: HER2+ cancers can be either HR+ or HR- (triple-positive vs. HER2+/HR-). Triple-positive tumors receive both HER2-targeted therapy and endocrine therapy.

Triple-negative breast cancer lacks all three receptors (ER-, PR-, HER2-). It tends to be more aggressive, grows faster, and is more common in younger women and women with BRCA1 mutations. However, TNBC is also the subtype most likely to achieve a pathologic complete response (pCR) to neoadjuvant chemotherapy — and patients who achieve pCR have excellent long-term outcomes.

Treatment backbone: Chemotherapy remains central. The addition of pembrolizumab (immunotherapy) to neoadjuvant chemotherapy followed by adjuvant pembrolizumab is now standard for early-stage TNBC (KEYNOTE-522 trial). Sacituzumab govitecan (Trodelvy) has become a key treatment for metastatic TNBC. PARP inhibitors (olaparib, talazoparib) are effective for BRCA-mutated TNBC.

Key consideration: All TNBC patients should undergo BRCA1/2 genetic testing, as results directly affect treatment options. PD-L1 testing guides immunotherapy decisions in the metastatic setting.

HER2-low breast cancer is not a new subtype but a newly actionable category. These tumors have low levels of HER2 expression (IHC 1+ or IHC 2+/ISH-negative) — not enough to qualify as HER2-positive, but enough to be targeted by newer antibody-drug conjugates.

The DESTINY-Breast04 trial demonstrated that trastuzumab deruxtecan (T-DXd) significantly improved survival in patients with HER2-low metastatic breast cancer who had received prior chemotherapy. This means that roughly half of previously “HER2-negative” patients now have a targeted therapy option.

Key consideration: Ask your pathologist specifically whether your tumor is HER2-low (IHC 1+ or IHC 2+/ISH-negative) versus HER2-zero (IHC 0). This distinction now has direct treatment implications.

The diagnostic pathway usually proceeds through several steps:

• Imaging: Diagnostic mammogram and breast ultrasound are first-line. Breast MRI may be added for high-risk patients, lobular cancers, or when the extent of disease is unclear.
• Biopsy: A core needle biopsy confirms the diagnosis and provides tissue for receptor testing (ER, PR, HER2, Ki-67). This is preferred over fine-needle aspiration because it provides more tissue for complete testing.
• Receptor and biomarker testing: ER status, PR status, HER2 status (IHC and, if equivocal, ISH/FISH), and Ki-67 proliferation index. These results define the subtype and should be available before treatment planning begins.
• Staging imaging: For early-stage disease, chest X-ray or CT and blood work may suffice. For locally advanced or suspected metastatic disease, CT of chest/abdomen/pelvis, bone scan, and sometimes PET/CT are used to assess distant spread.

Breast cancer staging uses the TNM system, now incorporating biologic factors:

• T (Tumor size): T1 (≤2 cm), T2 (2–5 cm), T3 (>5 cm), T4 (chest wall or skin involvement).
• N (Nodes): N0 (no lymph node involvement), N1 (1–3 axillary nodes), N2 (4–9 nodes or internal mammary nodes), N3 (10+ nodes or infraclavicular/supraclavicular nodes).
• M (Metastasis): M0 (no distant spread) or M1 (distant metastases — most commonly bone, liver, lungs, or brain).

Since 2018, the AJCC staging system also incorporates tumor grade, ER/PR status, HER2 status, and genomic assay results into the prognostic stage. This means two tumors of the same size and node status can be different stages based on their biology — reflecting how important subtype is to prognosis.

The pathology report from the biopsy and eventually from surgery is the definitive document. Key elements to review with the medical team:

• Invasive carcinoma type: Ductal (most common), lobular, or other special types.
• Grade: 1 (low), 2 (intermediate), or 3 (high) — reflects how abnormal cells look and how fast they divide.
• ER and PR status: Positive or negative, and the percentage of cells staining positive.
• HER2 status: Negative (IHC 0), low (IHC 1+ or IHC 2+/ISH-negative), or positive (IHC 3+ or IHC 2+/ISH-positive).
• Ki-67: A measure of how actively the cancer cells are dividing. Higher Ki-67 suggests more aggressive behavior.
• Lymphovascular invasion: Whether cancer cells are found in blood vessels or lymph channels.
• Margins: After surgery, whether the edges of the removed tissue are free of cancer.
• Lymph node status: Number of nodes examined and number containing cancer.

Genetic testing can feel abstract or even frightening, so it helps to understand what it concretely changes. There are two different kinds, and they answer different questions. Germline testing looks at the DNA you were born with (from blood or saliva) to see whether you inherited a mutation — such as in BRCA1 or BRCA2 — that raises cancer risk. Tumor genomic testing (like Oncotype DX) instead analyzes the cancer itself to predict how it will behave and whether chemotherapy will help. Both guide treatment, but in different ways.

A germline result can change your care in three concrete ways. First, it can open up specific treatments: if you carry a BRCA mutation, a class of pills called PARP inhibitors (olaparib, talazoparib) may become part of your treatment, in both early-stage and advanced disease. Second, it can influence surgery — some women who carry a high-risk mutation choose more extensive surgery to lower the risk of a future, separate cancer. Third, it has implications for your family: a mutation found in you can be looked for in relatives, who can then take steps to lower their risk or catch cancer early. For these reasons, testing is increasingly offered early and broadly — many centers now test everyone with a new invasive breast cancer.

The tumor genomic assays answer a question that worries many patients: “Do I really need chemotherapy?” For many hormone-receptor-positive, early-stage cancers, these tests can show that chemotherapy would add little or nothing, allowing you to safely avoid it — or, conversely, identify the smaller group who genuinely benefit. They turn a difficult guess into an evidence-based decision, and are a major reason fewer women need chemotherapy today than a decade ago.

Practical advice: ask whether both kinds of testing apply to you, and ask to speak with a genetic counselor for germline testing. Counselors help you understand the result, its limits, and its meaning for relatives, and they can address worries about insurance and privacy before you decide whether to test.

Germline testing looks for inherited mutations that predispose to cancer. BRCA1 and BRCA2 are the most well-known, but several other genes are now routinely tested.

• BRCA1 mutations: Increase lifetime breast cancer risk to 55–72% and ovarian cancer risk to 39–44%. Strongly associated with triple-negative subtype. Relevant to surgical decisions (bilateral mastectomy consideration) and unlock PARP inhibitor therapy.
• BRCA2 mutations: Increase lifetime breast cancer risk to 45–69% and ovarian cancer risk to 11–17%. Associated with HR+ and HER2+ subtypes. Also unlock PARP inhibitor therapy.
• Other high-penetrance genes: PALB2 (comparable risk to BRCA2), TP53 (Li-Fraumeni syndrome), CDH1 (lobular cancer and gastric cancer risk), PTEN (Cowden syndrome), STK11 (Peutz-Jeghers syndrome).
• Moderate-penetrance genes: ATM, CHEK2 — moderately elevated breast cancer risk. These may influence surgical and screening decisions but do not currently qualify for PARP inhibitor therapy.

Who should be tested: NCCN guidelines now recommend genetic counseling and testing for all breast cancer patients diagnosed at age 65 or younger, all patients with triple-negative breast cancer regardless of age, all patients with lobular breast cancer with a family history, those with a family history of breast, ovarian, pancreatic, or prostate cancer, those with bilateral breast cancer, male breast cancer patients, and those of Ashkenazi Jewish descent.

Why it matters for the family: A confirmed BRCA or other pathogenic mutation has direct implications for blood relatives. First-degree relatives have a 50% chance of carrying the same mutation. Cascade testing can identify at-risk family members who can then begin enhanced screening or consider risk-reducing strategies.

Genomic assays analyze the tumor’s own gene activity to predict the benefit of chemotherapy and the risk of recurrence. They are most relevant for HR+/HER2- early breast cancer, where the chemotherapy decision is often uncertain.

• Oncotype DX (21-gene recurrence score): The most widely used assay for HR+/HER2- node-negative and node-positive (1–3 nodes) disease. Produces a score from 0 to 100. The TAILORx and RxPONDER trials established that patients with low scores can safely skip chemotherapy.
• MammaPrint (70-gene signature): Classifies tumors as low-risk or high-risk. The MINDACT trial showed that patients with clinically high-risk but genomically low-risk tumors can safely forgo chemotherapy.
• Prosigna / PAM50 and EndoPredict: Additional validated assays that provide prognostic and sometimes predictive information.

What the scores mean practically:

• For node-negative HR+/HER2- disease: Oncotype DX score ≤25 generally means chemotherapy can be omitted (TAILORx).
• For node-positive (1–3 nodes) HR+/HER2- disease in postmenopausal women: Oncotype DX score ≤25 means chemotherapy can be omitted (RxPONDER). For premenopausal women, the benefit of chemotherapy is likely partly through ovarian suppression, and the decision is more nuanced.

PD-L1 is a protein on cancer cells or surrounding immune cells that helps cancer evade the immune system. PD-L1 testing is primarily relevant for triple-negative breast cancer, where a positive result (combined positive score ≥10) guides immunotherapy decisions in the metastatic setting. For early-stage TNBC, pembrolizumab is recommended regardless of PD-L1 status based on KEYNOTE-522.

• Has it been tested in breast cancer specifically, in your subtype, in a randomized trial?
• Is it recommended in the NCCN or ESMO guidelines?
• Could it interfere with your standard treatment (endocrine therapy, chemotherapy, targeted therapy)?
• Does anyone with no financial stake in it recommend it?
• Are oncologists at major breast cancer centers using it?

Be especially cautious of anyone who sells the product they recommend, and of anyone who suggests that standard care is harmful or unnecessary. This advice has cost lives. Build on standard care, never abandon it.

Supplement caution: Many supplements interact with endocrine therapy. Soy supplements, black cohosh, and certain herbal preparations can interfere with tamoxifen or aromatase inhibitors. Every supplement must be reviewed with the oncology team before use.

The period right after diagnosis is often the hardest psychologically, precisely because it is the time of greatest uncertainty and the least information. It helps to know that breast cancer is almost never an emergency requiring treatment within days — you generally have a few weeks to gather information, get your results, and make decisions carefully. The urge to “do something immediately” is understandable, but the most valuable early move is usually to slow down enough to get the full picture before committing to a plan.

A few concrete steps make the chaos more manageable. Ask for copies of your pathology report and imaging, and confirm that the full receptor testing (ER, PR, HER2) is complete — this is the information that determines everything that follows. Bring a trusted person to appointments to be a second set of ears and to take notes, because it is genuinely difficult to absorb complex information under stress. Write your questions down beforehand. And consider a second opinion, especially at a specialized breast or comprehensive cancer center — for most breast cancers a second opinion does not meaningfully delay care and often either confirms the plan (which is reassuring) or refines it.

It also helps to identify, early, who your points of contact will be: the nurse navigator (many centers assign one) who can answer questions between visits, and the social worker who can help with the practical and emotional load. Tell your team how much detail you want — some people want every statistic, others want the headline and a plan; both are valid, and a good team will meet you where you are.

Finally, be gentle with yourself about the emotional whiplash. Fear, anger, numbness, and difficulty sleeping are normal reactions, not signs you are coping badly. The intensity usually eases once your diagnosis is fully characterized and you have a concrete plan in hand — moving from the unknown to a defined path is itself one of the most powerful sources of relief.

• Bring a second person to every appointment. One listens and asks questions; the other writes things down.
• Ask permission to record. Most clinics allow phone recording. A recording you can replay later is invaluable.
• Keep a single folder — paper or digital — with every report: biopsy pathology, imaging, receptor results, genomic assay results, operative reports, and lab work.
• Write down questions in advance and bring them to every visit. It is easy to forget in the moment.

For the spouse, partner, family member, or friend walking alongside the patient: the first weeks set the tone. The most helpful things you can do right now are to be present at appointments and take notes, help organize the records folder, handle logistics (scheduling, insurance calls, meal coordination) so the patient can focus on medical decisions, and resist the urge to fix everything — sometimes just being there is enough.

• ☐ Diagnosis confirmed on core needle biopsy pathology report
• ☐ Receptor status confirmed: ER, PR, HER2 (including IHC score and ISH if needed), Ki-67
• ☐ Subtype determined: HR+/HER2-, HER2+, TNBC, or HER2-low
• ☐ Staging imaging completed as appropriate for stage
• ☐ Genetic counseling and BRCA/multi-gene panel testing discussed and ordered if indicated
• ☐ Genomic assay (Oncotype DX, MammaPrint) discussed if HR+/HER2- early-stage
• ☐ Fertility preservation discussed if premenopausal and considering chemotherapy
• ☐ Treating center and breast surgeon identified — confirm multidisciplinary breast cancer expertise
• ☐ Neoadjuvant therapy discussed (especially for HER2+ and TNBC)
• ☐ Records folder started: all pathology, imaging, labs in one place
• ☐ Second opinion considered, especially for complex or advanced disease
• ☐ Financial counselor contacted at the treating center

Breast cancer is almost never a same-day emergency, so this clock is about being thorough, not rushed. The dates are typical targets — your team sets the exact pace for your situation.

• ☐ First 48 hours: Request written copies of the biopsy pathology report and confirm which receptor tests (ER, PR, HER2, Ki-67) are complete or still pending. Ask: "Is my full receptor panel — ER, PR, and HER2 — back yet, and what is my exact subtype?"
• ☐ Within the first week: Confirm your subtype (HR+/HER2-, HER2+, triple-negative, or HER2-low) and ask whether germline genetic testing is indicated. Ask: "Should I have BRCA and multi-gene panel testing, and could the result change my surgery or drug options?"
• ☐ Within two weeks: For HR+/HER2- early-stage disease, ask whether a genomic assay will be used before any chemotherapy decision. Ask: "Will an Oncotype DX or MammaPrint score be used to decide whether I need chemotherapy, and when will we have it?"
• ☐ Within two weeks: If you are premenopausal and chemotherapy is possible, ask about fertility preservation before treatment starts. Ask: "If treatment could affect my fertility, can I see a fertility specialist before we begin?"
• ☐ In the first month: Confirm the sequence of your plan — surgery first versus neoadjuvant (pre-surgery) therapy — and how it is matched to your subtype. Ask: "Is surgery first or treatment first best for my subtype, and what are you hoping that sequence achieves?"
• ☐ In the first month: Identify your nurse navigator and financial counselor, and consider a second opinion at a specialized breast center.

One of the most emotionally charged early decisions is the choice between lumpectomy (removing the tumor and a margin of healthy tissue) and mastectomy (removing the whole breast). The most important thing to know is that, for most early-stage cancers, the two are equivalent for survival when lumpectomy is paired with radiation. This means the decision is often less about living longer and more about your values, your anatomy, and how you want to balance the extent of surgery against the need for radiation and the appearance and sensation of your breast.

Several practical factors shape the choice. Lumpectomy is less invasive, preserves the breast, and has a quicker recovery, but it usually requires several weeks of radiation afterward and leaves a small chance the cancer could return in the remaining breast tissue. Mastectomy removes more tissue and may avoid radiation in some cases, but it is bigger surgery with a longer recovery and raises the question of reconstruction. Tumor size relative to breast size, whether there are multiple areas of tumor, your genetic results, and your own feelings about keeping or removing the breast all factor in. There is rarely a single “right” answer — it is genuinely a personal decision made with your surgeon.

Reconstruction, if you have a mastectomy, is its own set of choices: implant-based or using your own tissue, done at the same time as the cancer surgery or later, and on one or both sides. A plastic surgeon experienced in breast reconstruction should ideally be part of the conversation before the cancer surgery, because the cancer operation can sometimes be planned to make reconstruction easier. Going flat (no reconstruction) is also a valid, healthy choice that many women make.

Two reassurances are worth holding onto. Removing more breast tissue does not, by itself, make you live longer in average-risk one-sided cancer — so choosing the less extensive option when it is appropriate is not “settling.” And it is always reasonable to ask for the time, and the second opinion, you need to make a decision you will be at peace with.

Lumpectomy removes the tumor with a margin of normal tissue while preserving the rest of the breast. It is followed by radiation therapy. Multiple large trials with decades of follow-up have shown that lumpectomy plus radiation achieves the same survival as mastectomy for most patients with early-stage disease.

Candidates for lumpectomy generally have a tumor that can be removed with clear margins and acceptable cosmetic results. Factors that may favor mastectomy include large tumor size relative to breast size, multicentric disease (cancer in multiple quadrants), inability to receive radiation, certain genetic mutations (BRCA1/2), or strong patient preference.

Mastectomy removes the entire breast. Options include simple (total) mastectomy, skin-sparing mastectomy, and nipple-sparing mastectomy — the latter two are designed to facilitate reconstruction.

Reconstruction options: Implant-based reconstruction (tissue expander followed by permanent implant), autologous tissue reconstruction (using the patient’s own tissue, such as DIEP flap or latissimus dorsi flap), or a combination. Reconstruction can be immediate (at the time of mastectomy) or delayed. A plastic surgeon experienced in breast reconstruction should be consulted before the mastectomy is scheduled.

Bilateral mastectomy: Removing both breasts is appropriate for patients with BRCA1/2 or other high-risk mutations and is chosen by some patients for peace of mind. However, for average-risk patients with unilateral cancer, contralateral prophylactic mastectomy has not been shown to improve survival. This should be a carefully weighed decision with the surgical team.

Lymph node evaluation determines whether cancer has spread beyond the breast. The standard approach for clinically node-negative patients is sentinel lymph node biopsy (SLNB) — removing the first one to three lymph nodes that drain the tumor.

If sentinel nodes are negative, no further axillary surgery is needed. If one to two sentinel nodes contain cancer, the ACOSOG Z0011 trial showed that for patients undergoing lumpectomy with planned radiation, full axillary lymph node dissection can often be omitted without compromising outcomes — sparing patients significant arm morbidity.

For patients who have had neoadjuvant therapy and initially had positive nodes, sentinel node biopsy after treatment can help assess response and guide axillary management. Clipping the involved node before starting neoadjuvant therapy helps ensure it is identified at surgery.

• Am I a candidate for lumpectomy, or is mastectomy recommended? Why?
• If mastectomy, what reconstruction options are available, and can I meet the plastic surgeon before the operation?
• How will the lymph nodes be evaluated?
• What are the cosmetic outcomes I should expect?
• Should I consider neoadjuvant therapy before surgery?
• How many breast cancer surgeries do you perform per year?

• After lumpectomy: Radiation to the remaining breast tissue is standard and is what makes lumpectomy equivalent to mastectomy in terms of survival.
• After mastectomy: Radiation to the chest wall and/or regional lymph nodes is recommended when the tumor was large (generally >5 cm), when four or more lymph nodes were involved, or when margins were close or positive.
• Hypofractionated regimens: Shorter radiation courses (three to four weeks instead of five to six) are now standard for most patients after lumpectomy, based on large trials showing equivalent outcomes with fewer side effects. Ask the radiation oncologist about this option.
• Partial breast irradiation: For select low-risk patients, radiation can be directed to only the tumor bed rather than the whole breast, further reducing treatment time and side effects.

Common side effects include skin redness and irritation (similar to sunburn), fatigue, and breast swelling. Most are temporary. Long-term effects can include changes in breast appearance and texture, lymphedema (arm swelling) if regional nodes are treated, and a very small increased risk of heart problems if the left breast is treated (modern techniques like deep inspiration breath hold significantly reduce cardiac dose).

It can seem backward to give chemotherapy or other drugs before removing the tumor — many people's instinct is to “get it out” first. But for HER2-positive and triple-negative cancers in particular, treating before surgery (called neoadjuvant therapy) has real advantages, and it has become the standard approach rather than an unusual one.

The first advantage is information that cannot be obtained any other way. When the tumor is treated before surgery, the surgeon and pathologist can see exactly how well it responded — sometimes the cancer disappears completely (a “pathologic complete response”). That response is one of the strongest predictors of long-term outcome, and, crucially, it now guides what happens next: patients whose cancer does not fully respond can be switched to additional or different treatment afterward to lower the risk of recurrence. Going straight to surgery forfeits this chance to learn from, and adjust, the treatment.

The second advantage is practical: shrinking a tumor before surgery can turn a mastectomy into a lumpectomy, or make a large tumor easier to remove with a better cosmetic result. For some patients it also provides time to complete genetic testing and plan reconstruction.

It is natural to worry that “leaving the cancer in” during months of pre-surgery treatment is dangerous, but for these subtypes the evidence is clear that outcomes are at least as good — and the ability to tailor later treatment is a genuine benefit. If your team recommends neoadjuvant therapy, it is worth asking what response they are hoping for and how the result will shape the rest of your plan, so you understand the strategy behind the sequence.

• Tumor shrinkage: May convert a patient who needs mastectomy into a lumpectomy candidate.
• Test treatment response: Seeing how the tumor responds to therapy in real time provides critical prognostic information. Achieving a pathologic complete response (pCR — no cancer remaining at surgery) is associated with excellent long-term outcomes.
• Guide adjuvant therapy: If cancer remains after neoadjuvant treatment, additional targeted therapy can be given (T-DM1 for HER2+ per KATHERINE; capecitabine for TNBC per CREATE-X).
• Earlier treatment of micrometastatic disease: Systemic therapy begins sooner, addressing any microscopic spread.

• HER2+: Taxane-based chemotherapy plus trastuzumab and pertuzumab (dual HER2 blockade). The CLEOPATRA framework established dual blockade as superior. pCR rates of 50–70% are achievable.
• TNBC: Anthracycline and taxane-based chemotherapy plus pembrolizumab (KEYNOTE-522). The addition of carboplatin has also improved pCR rates. pCR rates of 60–65% are now achievable with modern regimens.
• HR+/HER2-: Neoadjuvant chemotherapy is used for larger tumors or when downstaging to allow breast conservation. Neoadjuvant endocrine therapy (aromatase inhibitor for 4–6 months) is an option for postmenopausal patients with strongly HR+ tumors, particularly when chemotherapy is not planned.

Residual disease (cancer remaining at surgery after neoadjuvant therapy) is not a treatment failure — it is actionable information. Specific post-neoadjuvant strategies have been proven to improve outcomes:

• HER2+ with residual disease: Ado-trastuzumab emtansine (T-DM1, Kadcyla) replaces standard trastuzumab, based on the KATHERINE trial showing a 50% reduction in recurrence.
• TNBC with residual disease: Capecitabine (Xeloda) for 6–8 cycles, based on the CREATE-X trial. Pembrolizumab is continued as adjuvant therapy per KEYNOTE-522.
• TNBC with BRCA mutation and residual disease: Olaparib (a PARP inhibitor) for one year, based on the OlympiA trial.

All HR+ breast cancers receive endocrine therapy after surgery (and after chemotherapy, if given). The duration is typically five years, extended to seven or ten years for higher-risk patients.

• Premenopausal women: Tamoxifen is the standard starting point. For higher-risk patients, ovarian function suppression (OFS) with a GnRH agonist plus an aromatase inhibitor or tamoxifen is recommended based on the SOFT and TEXT trials.
• Postmenopausal women: Aromatase inhibitors (letrozole, anastrozole, or exemestane) are preferred. Switching strategies (tamoxifen for 2–3 years followed by an aromatase inhibitor, or vice versa) are also used.

CDK4/6 inhibitors block proteins that drive cancer cell division. Three drugs are approved: palbociclib (Ibrance), ribociclib (Kisqali), and abemaciclib (Verzenio).

Standard doses (FDA labels, as of July 2026): abemaciclib (Verzenio) 150 mg twice daily; ribociclib (Kisqali) 400 mg once daily in the adjuvant setting or 600 mg once daily for metastatic disease, each taken 21 days on then 7 days off; palbociclib (Ibrance) 125 mg once daily, 21 days on then 7 days off. In the early-stage setting, adjuvant abemaciclib is given for 2 years and adjuvant ribociclib for 3 years.

In the adjuvant (early-stage) setting:

• Abemaciclib: The monarchE trial showed that adding abemaciclib to endocrine therapy for two years in patients with high-risk HR+/HER2- early breast cancer (node-positive with additional risk factors) reduced the risk of recurrence. The benefit has been sustained at four-year follow-up. This is now a standard recommendation for eligible high-risk patients.
• Ribociclib: The NATALEE trial showed that adding ribociclib to endocrine therapy for three years improved invasive disease-free survival in a broader population of stage II–III HR+/HER2- breast cancer. This has expanded the pool of patients who may benefit from adjuvant CDK4/6 inhibition.
• Palbociclib: The PALLAS and PENELOPE-B trials did not show adjuvant benefit for palbociclib. Its role remains in the metastatic setting.

In the metastatic setting: All three CDK4/6 inhibitors combined with endocrine therapy are standard first-line treatment for metastatic HR+/HER2- breast cancer. The PALOMA, MONALEESA, and MONARCH trials established this approach. Ribociclib has demonstrated an overall survival benefit in multiple trials.

For HR+/HER2- early breast cancer, the question of whether to add chemotherapy to endocrine therapy is guided by genomic assays:

• TAILORx trial: For node-negative disease, patients with Oncotype DX recurrence scores of 0–25 did not benefit from adding chemotherapy to endocrine therapy. Those with scores of 26 or higher did benefit.
• RxPONDER trial: For node-positive (1–3 nodes) disease, postmenopausal women with scores ≤25 did not benefit from chemotherapy. For premenopausal women, the benefit appeared to be partly mediated through chemotherapy-induced ovarian suppression, making the decision more complex and requiring careful discussion.

These trials have spared tens of thousands of patients from unnecessary chemotherapy while identifying those who truly benefit from it.

• Has a genomic assay (Oncotype DX or MammaPrint) been ordered? What does my score mean for the chemotherapy decision?
• Am I a candidate for adjuvant CDK4/6 inhibitor therapy (abemaciclib or ribociclib)? What is the expected benefit given my risk level? Ask: "Based on my genomic score and nodes, do I need chemotherapy, endocrine therapy alone, or endocrine therapy plus a CDK4/6 inhibitor?"
• What endocrine therapy do you recommend, and for how long?
• If I am premenopausal, should ovarian function suppression be added?
• What side effects should I expect from endocrine therapy, and how will we manage them?
• What is my risk of late recurrence (beyond five years), and does that affect the treatment duration?

• Trastuzumab (Herceptin): The original HER2-targeted antibody. Given for one year total in the adjuvant/neoadjuvant setting. Transformed HER2+ breast cancer outcomes beginning in 2005.
• Pertuzumab (Perjeta): A second anti-HER2 antibody that binds a different part of the HER2 receptor. Used in combination with trastuzumab (dual blockade) for neoadjuvant and metastatic treatment, and selectively in the adjuvant setting for high-risk patients.
• Ado-trastuzumab emtansine (T-DM1, Kadcyla): An antibody-drug conjugate that delivers chemotherapy directly to HER2+ cells. Standard adjuvant therapy for patients with residual disease after neoadjuvant treatment (KATHERINE trial).
• Trastuzumab deruxtecan (T-DXd, Enhertu): A newer antibody-drug conjugate with a potent topoisomerase inhibitor payload. Has shown remarkable efficacy in metastatic HER2+ disease (DESTINY-Breast03 showed superiority over T-DM1 in second-line) and has expanded the treatment landscape to HER2-low tumors (DESTINY-Breast04).
• Tucatinib (Tukysa): A small-molecule HER2 inhibitor that crosses the blood-brain barrier. Particularly valuable for patients with brain metastases (HER2CLIMB trial).
• Neratinib (Nerlynx): Another small-molecule HER2 inhibitor used as extended adjuvant therapy after trastuzumab in selected high-risk patients (ExteNET trial). Main side effect is diarrhea, managed with prophylactic loperamide.
• Margetuximab (Margenza): An engineered anti-HER2 antibody with enhanced immune cell activation (SOPHIA trial).

Representative doses (FDA labels, as of July 2026): trastuzumab (Herceptin) 8 mg/kg IV loading then 6 mg/kg every 3 weeks (or 4 mg/kg then 2 mg/kg weekly), for 52 weeks total; ado-trastuzumab emtansine (T-DM1, Kadcyla) 3.6 mg/kg IV every 3 weeks for 14 cycles when there is residual disease after neoadjuvant therapy; trastuzumab deruxtecan (Enhertu) 5.4 mg/kg IV every 3 weeks.

The standard approach for most HER2+ breast cancers larger than 2 cm or node-positive:

1. Neoadjuvant: Taxane-based chemotherapy plus trastuzumab and pertuzumab. An anthracycline may be added. Goal: achieve pathologic complete response (pCR).
2. Surgery: Lumpectomy or mastectomy with sentinel node biopsy.
3. Adjuvant (based on surgical pathology):
   • If pCR achieved: Complete one year of trastuzumab (with or without pertuzumab for high-risk cases).
   • If residual disease: Switch to T-DM1 (Kadcyla) to complete 14 cycles (KATHERINE trial — 50% reduction in recurrence).
4. Radiation: As indicated by surgical approach and disease extent.
5. Endocrine therapy: If also HR+ (triple-positive), add endocrine therapy per HR+ guidelines.

For small (T1a/b), node-negative HER2+ tumors: The APT trial established that paclitaxel plus trastuzumab (without anthracycline) for 12 weeks followed by trastuzumab to complete one year achieves excellent outcomes with less toxicity.

HER2-targeted therapies, particularly trastuzumab, can affect heart function. Cardiac monitoring with echocardiograms or MUGA scans every three months during treatment is standard. Ask: "What HER2-targeted drugs am I getting, how often will my heart function (LVEF) be checked, and what result would make you pause treatment?" Most cardiac effects are reversible if caught early and managed by holding or adjusting therapy. Patients with pre-existing heart conditions should be evaluated by a cardiologist before starting HER2-targeted treatment.

The KEYNOTE-522 trial established the current standard: pembrolizumab (an immune checkpoint inhibitor) added to neoadjuvant chemotherapy (carboplatin, paclitaxel, then doxorubicin/cyclophosphamide), followed by adjuvant pembrolizumab after surgery. This approach improved both pCR rates and event-free survival.

Key results: pCR rates improved from roughly 51% with chemotherapy alone to approximately 63% with the addition of pembrolizumab. Event-free survival was significantly improved, particularly in patients with PD-L1-positive tumors and those who did not achieve pCR.

For patients with residual disease after neoadjuvant therapy, pembrolizumab is continued as adjuvant therapy per KEYNOTE-522, and capecitabine may also be added based on the CREATE-X trial. Pembrolizumab (Keytruda) is dosed 200 mg IV every 3 weeks or 400 mg IV every 6 weeks per the FDA label.

For patients with BRCA1 or BRCA2 germline mutations:

• Adjuvant olaparib (OlympiA trial): One year of olaparib after standard treatment (including neoadjuvant therapy) for patients with BRCA-mutated, HER2-negative early breast cancer with high-risk features significantly improved invasive disease-free survival and overall survival. Olaparib (Lynparza) is dosed 300 mg twice daily per the FDA label. This is now standard for eligible patients.
• Metastatic setting: Both olaparib (OlympiAD trial) and talazoparib (EMBRACA trial) are approved for BRCA-mutated, HER2-negative metastatic breast cancer.

This is why BRCA testing is so important for all TNBC patients — it directly unlocks additional treatment options.

• First-line: Pembrolizumab plus chemotherapy for PD-L1-positive tumors (KEYNOTE-355). For PD-L1-negative tumors, chemotherapy alone remains standard, with the specific agent chosen based on prior treatment and patient factors.
• Sacituzumab govitecan (Trodelvy): An antibody-drug conjugate targeting Trop-2. The ASCENT trial showed significant improvement in progression-free and overall survival for patients with metastatic TNBC who had received two or more prior therapies. This has become a key later-line treatment.
• Datopotamab deruxtecan (Datroway): A Trop-2 antibody-drug conjugate FDA-approved (May 2026, TROPION-Breast02) for metastatic TNBC in patients who are not candidates for PD-1/PD-L1 immunotherapy — a first-line option for that group.
• Trastuzumab deruxtecan (T-DXd): For HER2-low TNBC (see the HER2-Low section).
• PARP inhibitors: For BRCA-mutated metastatic TNBC (olaparib or talazoparib).

The DESTINY-Breast04 trial enrolled patients with HER2-low (IHC 1+ or IHC 2+/ISH-negative) metastatic breast cancer who had received one or two prior lines of chemotherapy. Patients who received trastuzumab deruxtecan (T-DXd) had significantly longer progression-free survival and overall survival compared to physician’s choice chemotherapy.

This trial redefined how pathologists report HER2 and how oncologists think about treatment options for roughly half of previously “HER2-negative” patients.

What to do: Ask your pathologist to specify the exact HER2 IHC score (0, 1+, 2+, or 3+). If your tumor is IHC 1+ or IHC 2+/ISH-negative, you have HER2-low disease and may be eligible for T-DXd if standard treatments stop working.

Even very faint HER2 staining (previously scored as IHC 0 but with trace expression — the “HER2-ultralow” category) can respond to T-DXd. Based on the DESTINY-Breast06 trial (NCT04494425), T-DXd received FDA approval in January 2025 for HR+/HER2-negative metastatic breast cancer that is HER2-low or HER2-ultralow, after at least one line of endocrine therapy — expanding the population that benefits from this drug. (The earlier HER2-low approval, from the DESTINY-Breast04 trial, dates to August 2022.)

Endocrine (hormone-blocking) therapy is, for hormone-receptor-positive breast cancer, one of the most effective treatments that exists — but it works only if you keep taking it, often for five to ten years. This is genuinely hard. The benefit is invisible (you feel no different on the day you take a pill that is quietly lowering your recurrence risk), the side effects are real and daily, and the finish line is years away. Studies consistently find that a large fraction of women stop early or take their pills inconsistently — and that doing so measurably raises the risk the cancer comes back. Understanding this up front is one of the most useful things you can do to get the full protection these drugs offer.

The reason the long duration matters is the distinctive behavior of hormone-receptor-positive cancer: unlike some other subtypes, it can recur many years — even a decade or two — after the original diagnosis. Endocrine therapy continues to suppress that late risk the whole time you take it, which is why finishing the course, and sometimes extending it, is so strongly recommended. A missed year is not a small thing.

The good news is that most side effects are manageable, and the answer to intolerance is almost never to silently stop. Joint pain and stiffness (the most common reason women quit aromatase inhibitors) often improves with exercise, and sometimes with switching to a different aromatase inhibitor or to tamoxifen; hot flashes, bone loss, and sexual side effects all have specific management strategies, and bone health is monitored and protected throughout. The key is to tell your team before you stop — there is usually a workable adjustment.

Practical tips that help real people finish: build the pill into a fixed daily routine, use a phone reminder or a pill organizer, track and report side effects rather than enduring them in silence, and ask your team to treat tolerability as a problem to solve together. If finishing feels impossible, say so — a switch or dose adjustment that keeps you on some effective therapy is far better than stopping altogether.

• Tamoxifen: A selective estrogen receptor modulator (SERM) that blocks estrogen’s effect on breast cells. Used in premenopausal and postmenopausal women. Main side effects: hot flashes, increased risk of endometrial cancer and blood clots. The usual adjuvant dose is 20 mg once daily (FDA label); higher doses add no benefit. Typically taken for five years; may be extended to ten for higher-risk patients.
• Aromatase inhibitors (letrozole, anastrozole, exemestane): Block the enzyme that converts androgens to estrogen in postmenopausal women (or in premenopausal women whose ovaries are suppressed). Standard doses are letrozole 2.5 mg, anastrozole 1 mg, or exemestane 25 mg once daily (FDA labels). Main side effects: joint pain and stiffness, bone loss, hot flashes. Joint pain is the leading reason patients stop treatment early — management strategies exist and should be discussed.
• Ovarian function suppression (OFS): GnRH agonists (goserelin, leuprolide) suppress ovarian estrogen production in premenopausal women. Used in combination with tamoxifen or an aromatase inhibitor for higher-risk premenopausal patients. The SOFT trial showed improved outcomes with the addition of OFS.

Adherence to endocrine therapy is one of the most important modifiable factors in HR+ breast cancer outcomes. Studies show that up to half of patients stop early or take the medication inconsistently. Side effects are the primary reason.

• Joint pain (aromatase inhibitors): Regular exercise (especially walking, yoga, or strength training) has trial-level evidence for reducing joint symptoms. Switching between aromatase inhibitors or switching to tamoxifen can help. Some patients benefit from omega-3 supplements, acupuncture, or duloxetine.
• Hot flashes: Venlafaxine, gabapentin, oxybutynin, and behavioral strategies can help. Avoid estrogen-containing products. Fezolinetant (Veozah), a neurokinin-3 receptor antagonist, is a newer option.
• Bone health: Aromatase inhibitors accelerate bone loss. Baseline and periodic bone density scans (DEXA) are recommended. Weight-bearing exercise, calcium, vitamin D, and bisphosphonates or denosumab when indicated help protect bones.
• Vaginal dryness and sexual health: Non-hormonal vaginal moisturizers, lubricants, and pelvic floor physical therapy can help. For some patients, low-dose vaginal estrogen may be considered with careful oncologic oversight.

Key message: Do not stop endocrine therapy without discussing it with the oncology team. If side effects are intolerable, there are usually alternatives or management strategies. Stopping early significantly increases recurrence risk.

The standard minimum is five years. Extended therapy (seven to ten years) is considered for patients at higher risk of late recurrence: those with node-positive disease, large tumors, high-grade disease, or young age at diagnosis. The MA.17R and ATLAS trials showed benefit from extended therapy in selected patients, though the absolute benefit must be weighed against ongoing side effects.

A diagnosis of metastatic (stage IV) breast cancer is frightening, and it is important to be honest: it is generally not curable. But it is increasingly treatable, and the day-to-day reality for many people is very different from what the word “metastatic” once implied. With modern therapies — the targeted pills, antibody-drug conjugates, and immunotherapies described in this guide — many patients live for years, often with good quality of life, moving from one effective treatment to the next as needed. For a growing number, metastatic breast cancer is becoming something closer to a chronic illness managed over a long time than a short prognosis.

The treatment philosophy in this setting shifts in a way worth understanding. The goal is no longer to cure at all costs but to control the cancer while protecting how you feel and function — to live as well as possible for as long as possible. That usually means preferring the most effective therapy with the most tolerable side effects, often staying on gentler oral treatments while they keep working and changing only when the cancer progresses. It also means that quality of life, symptom control, and your own priorities become central, legitimate parts of the medical plan rather than afterthoughts.

Two things help enormously and are underused. The first is early palliative (supportive) care — which, despite its reputation, is not the same as hospice or “giving up.” It is a specialty focused on controlling pain, nausea, fatigue, and distress, and studies show it improves quality of life (and sometimes even length of life) when started early alongside cancer treatment. The second is clinical trials, which in metastatic disease are often a way to access tomorrow's treatments today and are worth asking about at every decision point, not only at the end.

Finally, give yourself permission to live. Many people with metastatic breast cancer work, travel, raise families, and pursue what matters to them for years. Connecting with others living with metastatic disease — through dedicated support communities — helps counter the isolation, and planning ahead (including practical and advance-care planning) is a way of taking control, not a sign of pessimism.

The primary goals in metastatic breast cancer are to prolong life, maintain quality of life, and control symptoms. Treatment is typically continuous, with sequential lines of therapy as each one eventually stops working. The choice of therapy depends on subtype, molecular features, prior treatments, sites of metastasis, and patient preferences.

For a small subset of patients with limited metastatic disease (oligometastatic), aggressive local treatment (surgery or radiation to metastatic sites) combined with systemic therapy may achieve prolonged remissions, though this remains an area of active research.

• First-line: CDK4/6 inhibitor plus endocrine therapy. All three CDK4/6 inhibitors (palbociclib, ribociclib, abemaciclib) are approved in this setting. Ribociclib has shown overall survival benefit in the MONALEESA trials.
• PIK3CA/AKT pathway: For PIK3CA-mutated tumors, inavolisib (Itovebi) was FDA-approved in 2024 with palbociclib + fulvestrant for endocrine-resistant disease (INAVO120). Other options: alpelisib (PIK3CA-mutated, SOLAR-1) and the AKT inhibitor capivasertib (Truqap), approved 2023 for PIK3CA/AKT1/PTEN-altered tumors (CAPItello-291).
• Second-line and beyond: Options include fulvestrant (if not previously used), the targeted agents above, mTOR inhibitors (everolimus, BOLERO-2 trial), antibody-drug conjugates (see below), and eventually chemotherapy.
• ESR1 mutations: Can develop during aromatase inhibitor treatment, causing resistance. Several oral agents are now FDA-approved specifically for ESR1-mutated metastatic HR+ disease after prior endocrine therapy: elacestrant (Orserdu), the first oral SERD (2023, EMERALD); imlunestrant (Inluriyo), an oral SERD (2025, EMBER-3); and vepdegestrant (Veppanu), the first PROTAC estrogen-receptor degrader (May 2026, VERITAC-2).

• First-line: Taxane plus trastuzumab and pertuzumab (CLEOPATRA trial).
• Second-line: Trastuzumab deruxtecan (T-DXd) based on DESTINY-Breast03 (showed superiority over T-DM1).
• Third-line and beyond: T-DM1, tucatinib-based combinations (especially for brain metastases, HER2CLIMB trial), lapatinib combinations, margetuximab.
• Brain metastases: HER2+ breast cancer has a higher risk of brain metastases. Tucatinib plus trastuzumab and capecitabine (HER2CLIMB) showed particular benefit for patients with brain involvement. T-DXd also has demonstrated intracranial activity.

Bone is the most common site of breast cancer metastasis, particularly in HR+ disease. Bone-modifying agents — zoledronic acid (Zometa) or denosumab (Xgeva) — reduce skeletal complications (fractures, pain, spinal cord compression) and are standard for all patients with bone metastases. Radiation therapy is highly effective for controlling bone pain.

• What is the molecular profile of my metastatic disease? Has it been re-biopsied and re-tested?
• What are the goals of this treatment — how long is it expected to work?
• What clinical trials am I eligible for?
• How will we monitor response, and how often?
• What palliative and supportive care resources are available?
• Should I get a second opinion at a major breast cancer center?

Many people picture clinical trials as a last resort — something you turn to only when standard treatment has run out. In breast cancer that picture is misleading. Trials run at every stage, including for newly diagnosed patients, and a striking number of today's standard treatments — CDK4/6 inhibitors, the antibody-drug conjugates, immunotherapy for triple-negative disease — were available only through trials a few years ago. Joining a trial is often a way to access tomorrow's care today, under unusually close monitoring, rather than a sign that your situation is dire.

It helps to understand a few realities that ease common worries. You will not be given a sugar pill instead of treatment: in cancer trials, a placebo (if used at all) is almost always given in addition to standard therapy, not in place of it, and the trial's design is explained to you in detail before you decide. You can leave a trial at any time, for any reason, without affecting your regular care. And trials have strict safety oversight, with frequent checks that can actually mean closer attention than routine treatment.

When weighing a specific trial, useful questions include: What is being tested, and how does it compare with my standard option? What extra visits, tests, or travel are involved, and who pays for them? What are the known risks, and how will they be monitored? A good trial team welcomes these questions, and asking them does not commit you to enrolling.

You do not have to find trials alone. Your oncologist, the cancer center's research office, and free services such as the NCI Cancer Information Service (1-800-4-CANCER) and major advocacy organizations can help match you to trials that fit your subtype, stage, and location. Because eligibility often depends on which treatments you have already had, it is worth asking about trials early rather than only after other options are exhausted.

• Neoadjuvant setting: I-SPY and similar adaptive platform trials test novel combinations before surgery, using pCR as an endpoint to rapidly identify promising drugs.
• Adjuvant setting: Trials testing new drug combinations, shorter or longer durations, and biomarker-guided approaches.
• Metastatic setting: Trials of new targeted drugs, antibody-drug conjugates, bispecific antibodies, and immunotherapy combinations.
• Treatment de-escalation: Trials testing whether some patients can safely receive less treatment (shorter chemotherapy, omitting radiation in selected cases).

• DESTINY-Breast06 (NCT04494425): Showed T-DXd benefit in HER2-low and HER2-ultralow HR+ metastatic breast cancer after endocrine therapy — the basis for T-DXd’s FDA approval in this earlier-line, post-endocrine setting.
• TROPION-Breast01 (NCT05104866): Testing datopotamab deruxtecan (Dato-DXd), a Trop-2-directed ADC, in HR+/HER2- metastatic breast cancer.
• KEYNOTE-756 (NCT03725059): Testing pembrolizumab in HR+/HER2- early breast cancer with high-risk features.
• CAPItello-292 (NCT04862663): Testing capivasertib added to a CDK4/6 inhibitor + fulvestrant in HR+/HER2- metastatic breast cancer.
• EMBER-3 (NCT04975308): Testing imlunestrant (a next-generation oral SERD) in ER+/HER2- metastatic breast cancer.
• I-SPY 2 (NCT01042379): An adaptive platform trial testing multiple new agents in the neoadjuvant setting.

All NCT numbers listed above should be verified on ClinicalTrials.gov.

• Start with the treating center’s clinical trials office.
• Search ClinicalTrials.gov — filter by breast cancer subtype, stage, and location.
• BreastCancerTrials.org — a matching service that helps patients find relevant trials.
• National Cancer Institute (1-800-4-CANCER) — free trial-matching service.
• Ask at a second-opinion visit at a major breast cancer center.

By federal law, most insurance plans must cover the routine care costs of clinical trial participation. The experimental drug is generally provided at no cost by the trial sponsor.

ADCs deliver potent chemotherapy directly to cancer cells by linking it to an antibody that targets a specific protein on the cancer surface. Several ADCs are in advanced development:

• Datopotamab deruxtecan (Dato-DXd, Datroway): Targets Trop-2, similar to sacituzumab govitecan but with a different linker-payload. Now FDA-approved — for HR+/HER2- metastatic disease after endocrine therapy and chemotherapy (2025, TROPION-Breast01), and for metastatic triple-negative breast cancer in patients who are not candidates for PD-1/PD-L1 immunotherapy (May 2026, TROPION-Breast02).
• Patritumab deruxtecan: Targets HER3, expanding the ADC approach beyond HER2 and Trop-2 (investigational).

ADCs represent one of the most active areas of breast cancer drug development, with multiple targets and combinations being explored.

• Oral SERDs (selective estrogen receptor degraders): Elacestrant (Orserdu) was the first approved oral SERD (2023). Imlunestrant (Inluriyo) is now also FDA-approved (2025, EMBER-3) for ESR1-mutated HR+/HER2- metastatic breast cancer after prior endocrine therapy. These overcome some resistance to aromatase inhibitors.
• Capivasertib (AKT inhibitor): Approved for PIK3CA/AKT1/PTEN-altered HR+/HER2- metastatic breast cancer (CAPItello-291). Expands targeted options beyond CDK4/6 inhibitors.
• PROTAC degraders: A new class of drugs that tag the estrogen receptor for destruction entirely rather than simply blocking it. In May 2026 the FDA approved vepdegestrant (Veppanu) — the first PROTAC (proteolysis-targeting chimera) medicine of any kind — for adults with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer whose disease has progressed after prior endocrine therapy, detected by an FDA-authorized test. In the phase 3 VERITAC-2 trial (NCT05654623), vepdegestrant roughly doubled progression-free survival versus fulvestrant in ESR1-mutated disease. It is a once-daily oral pill.

While immunotherapy has made the greatest impact in TNBC (KEYNOTE-522, KEYNOTE-355), efforts to extend its benefit to other subtypes are ongoing. Combinations of immunotherapy with CDK4/6 inhibitors, ADCs, and radiation are being tested. The challenge is that HR+ and some HER2+ tumors are less immunogenic, requiring strategies to make them more visible to the immune system.

Circulating tumor DNA (ctDNA) analysis from blood samples is emerging as a tool for monitoring treatment response, detecting resistance mutations, and potentially guiding early intervention. In breast cancer, ctDNA can detect ESR1 mutations that drive endocrine therapy resistance, identify emerging resistance earlier than imaging, and potentially guide adjuvant therapy decisions (though this remains investigational for breast cancer, with trials like c-TRAK TN and ZEST ongoing).

• High-dose chemotherapy with bone marrow transplant FAILED
  In the 1990s, high-dose chemotherapy with autologous stem cell rescue was widely promoted for high-risk and metastatic breast cancer. Multiple randomized trials showed no survival benefit over standard-dose chemotherapy, with significantly more toxicity and treatment-related deaths. This approach was abandoned.
• Bevacizumab (Avastin) for metastatic breast cancer DE-ADOPTED
  The FDA initially granted accelerated approval for bevacizumab in metastatic breast cancer based on progression-free survival data (E2100 trial). However, subsequent confirmatory trials failed to show an overall survival benefit, and the FDA revoked the breast cancer indication in 2011. Bevacizumab remains approved for other cancers but is no longer standard for breast cancer.
• Ixabepilone for metastatic breast cancer DE-ADOPTED
  While technically still FDA-approved, ixabepilone has been largely replaced by more effective agents (eribulin, ADCs) and is rarely used in current practice.
• Routine complete axillary lymph node dissection for minimal sentinel node disease DE-ADOPTED
  The ACOSOG Z0011 trial showed that patients with one to two positive sentinel nodes undergoing lumpectomy with radiation can safely omit full axillary dissection. This spared many patients from lymphedema and arm morbidity.
• Halsted radical mastectomy DE-ADOPTED
  The disfiguring radical mastectomy (removing the breast, underlying chest muscles, and all axillary nodes) was the standard for a century until the NSABP B-04 and B-06 trials proved that less extensive surgery achieved equivalent survival. Modified radical mastectomy and breast-conserving surgery replaced it.
• Lapatinib as adjuvant therapy FAILED
  The ALTTO trial tested adding lapatinib to trastuzumab in the adjuvant setting for HER2+ breast cancer. It did not improve outcomes and added toxicity. Pertuzumab (APHINITY trial) proved to be the better addition to trastuzumab.

2000 Circle of Hope Drive, Salt Lake City, UT 84112
Main / new patients: 801-587-7000

NCI-designated Comprehensive Cancer Center for the Mountain West. Multidisciplinary breast cancer program with dedicated breast surgical oncologists, medical oncologists specializing in breast cancer, radiation oncologists, genetic counselors, and plastic surgeons. Active clinical trial portfolio. NCCN member institution.

Intermountain Medical Center (Murray): 801-507-7000
Utah Valley Hospital (Provo): 801-357-7850

Large regional health system with breast cancer programs, including breast imaging, surgical oncology, and medical oncology. Access to clinical trials through Intermountain’s research network.

500 Foothill Drive, Salt Lake City, UT 84148
Main: 801-582-1565

VA medical center providing oncology services to eligible veterans. Coordinates with Huntsman Cancer Institute for specialty care and clinical trials through the VA-HCI partnership.

1515 Holcombe Boulevard, Houston, TX 77030
New patients: 877-632-6789

One of the largest and highest-volume breast cancer programs in the world. Extensive clinical trial portfolio, comprehensive breast surgical oncology, and dedicated inflammatory breast cancer and male breast cancer programs.

New patients: 800-525-2225

Major breast cancer research and treatment center. Evelyn H. Lauder Breast Center with dedicated multidisciplinary breast cancer care. Strong programs in breast surgery innovation, genomic profiling, and clinical trials.

450 Brookline Avenue, Boston, MA 02215
New patients: 877-442-3324

Susan F. Smith Center for Women’s Cancers with a large dedicated breast oncology program. Strong clinical trials portfolio and translational research. Home to key investigators in HR+, HER2+, and TNBC research.

Rochester: 507-538-3270  |  Phoenix/Scottsdale: 480-301-8000  |  Jacksonville: 904-953-0853

Comprehensive breast cancer programs at all three campuses. Strong surgical and genetic counseling programs. Active in major national clinical trial networks.

• Johns Hopkins Sidney Kimmel Comprehensive Cancer Center (Baltimore, MD) — 410-955-8964. Pioneering work in breast cancer genomics and lobular breast cancer research.
• UCSF Helen Diller Family Comprehensive Cancer Center (San Francisco, CA) — 415-353-7070. Strong breast oncology and I-SPY trial leadership.
• UCLA Jonsson Comprehensive Cancer Center (Los Angeles, CA) — 310-825-2631.
• University of Colorado Cancer Center (Aurora, CO) — 720-848-0300. Nearest major academic center to Utah outside Huntsman.
• City of Hope (Duarte, CA) — 800-826-4673. Strong breast cancer program and active clinical trials.

MD Anderson, Memorial Sloan Kettering, Mayo Clinic, and Dana-Farber offer structured remote second-opinion programs that do not require travel.

• Princess Margaret Cancer Centre (Toronto, ON) — 416-946-4501. One of the world’s top five cancer centers. Comprehensive breast cancer program.
• BC Cancer Agency (Vancouver, BC) — 604-877-6000. Provincial cancer program with breast cancer specialization.
• Sunnybrook Odette Cancer Centre (Toronto, ON) — 416-480-4998. Large breast cancer program with clinical trial access.

• The Royal Marsden NHS Foundation Trust (London, UK) — Recognized breast cancer center with strong clinical trial program.
• Institut Gustave Roussy (Villejuif, France) — Major European cancer research center.
• European Institute of Oncology (IEO) (Milan, Italy) — Breast cancer program led by pioneers in oncoplastic surgery.

It is easy to think of breast cancer care as just the oncologist and the treatments, but the people who navigate it best usually build a broader support team early — before they are in crisis. Supportive care is not a sign that treatment is failing; it is what helps you get through treatment, feel better day to day, and complete the full course of therapy that gives you the best outcome. Asking for this help early is a strength, not a weakness.

Several kinds of support are worth seeking out from the start. A palliative or supportive-care team can manage symptoms like pain, nausea, fatigue, and neuropathy more expertly than cancer treatment alone — and, again, this is appropriate at any stage, not just advanced disease. A social worker can help with the practical avalanche a diagnosis brings: transportation, work and disability paperwork, and connecting you to resources. Mental-health support (counseling, support groups, or medication when needed) addresses the very real anxiety, depression, and fear that accompany cancer and that too many people suffer through alone. A nutritionist, physical therapist, or lymphedema specialist addresses specific, common problems before they become entrenched.

The financial side deserves special mention because it blindsides so many families. Treatment is expensive, and “financial toxicity” — the stress and hardship of paying for care — is itself a health problem that can affect outcomes. Ask early about a financial navigator or patient-assistance programs; drug manufacturers, hospital foundations, and nonprofits offer help that many people never learn about simply because they did not know to ask.

Practically, a good first step is to ask your cancer center: “Who is on my support team besides my oncologist, and how do I reach a social worker, a financial navigator, and supportive care?” Building those connections while you feel relatively well means they are already in place when you need them most.

• Nausea: Modern anti-nausea regimens are highly effective. Take medications on schedule, not just when nausea arrives.
• Fatigue: The most common side effect. Regular light exercise helps more than rest alone.
• Hair loss: Expected with most chemotherapy regimens. Scalp cooling (cold cap therapy) can reduce hair loss for some patients and regimens. Hair regrows after treatment, though texture and color may initially differ.
• Neuropathy: Tingling, numbness, or pain in hands and feet from taxanes. Report symptoms early — dose adjustments can prevent lasting damage.
• Low blood counts: Increase infection risk. A fever during chemotherapy is a medical emergency.

Lymphedema — swelling of the arm on the side of surgery — can develop after axillary surgery or radiation to the lymph nodes. Prevention strategies include avoiding blood pressure cuffs, blood draws, and IVs in the affected arm, gradual return to exercise, skin care to prevent infection, and early reporting of any arm swelling.

If lymphedema develops, a certified lymphedema therapist (CLT) provides the most effective management: complete decongestive therapy including manual lymphatic drainage, compression garments, and exercise. Early treatment produces the best results.

Multiple studies show that regular physical activity during and after breast cancer treatment improves fatigue, mood, physical function, and potentially survival. The general recommendation is 150 minutes per week of moderate-intensity exercise (brisk walking, swimming, cycling). Strength training is safe and beneficial, including for patients who have had lymph node surgery. An exercise physiologist or physical therapist with oncology experience can provide individualized guidance.

For premenopausal patients considering chemotherapy or extended endocrine therapy, fertility should be discussed before treatment begins. Options include egg or embryo freezing (the window is typically two to three weeks), GnRH agonists during chemotherapy to protect ovarian function (POEMS trial showed benefit), and ovarian tissue cryopreservation (less common). A reproductive endocrinologist should be consulted urgently at diagnosis, as some fertility preservation options have narrow time windows.

Palliative care is specialized care focused on symptom relief and quality of life. It should run alongside active treatment from the beginning — it is not the same as hospice. Studies show that early palliative care improves quality of life and in some settings even survival. Ask the oncology team for a referral to palliative care or supportive oncology services.

After completing primary treatment, structured follow-up includes regular physical exams, annual mammography, monitoring for treatment side effects, and ongoing endocrine therapy if applicable. Ask the oncology team for a written survivorship care plan that outlines the follow-up schedule, who is responsible for each component, and how to manage long-term effects of treatment.

• Build a team, not a single hero. Rotate caregiving duties. Scheduled time off for the primary caregiver is maintenance, not luxury.
• Set up help early: meal trains, rides, household help, childcare.
• Use coordination platforms like CaringBridge (caringbridge.org) or Lotsa Helping Hands.
• Access caregiver-specific resources: Family Caregiver Alliance (caregiver.org, 800-445-8106).

Anxiety, fear, body image concerns, and depression are normal responses to a breast cancer diagnosis. They are treatable, not signs of weakness. Resources include oncology social workers and psychologists, support groups (in-person and online), mindfulness-based stress reduction programs, and medication when appropriate. Many breast cancer centers offer dedicated psychosocial oncology services.

Body image and sexuality: Changes in appearance from surgery, hair loss, and treatment side effects can profoundly affect self-image and intimate relationships. These concerns are legitimate and worth raising with the medical team. Resources include Look Good Feel Better (lookgoodfeelbetter.org), specialized counselors, and peer support groups.

Children do better with honest, age-appropriate information. CancerCare (cancercare.org, 800-813-4673) and the American Cancer Society have resources for talking with children about a parent’s cancer. Many cancer centers have child-life specialists or family counselors.

• What is the exact diagnosis? What stage is this?
• What is my tumor’s receptor status: ER, PR, HER2, Ki-67?
• What subtype is this? HR+, HER2+, triple-negative, or HER2-low?
• Should I have genetic testing for BRCA and other genes?
• Is a genomic assay (Oncotype DX, MammaPrint) appropriate for my case?
• Should treatment start before surgery (neoadjuvant approach)?
• Will my case be discussed at a multidisciplinary tumor board?
• Am I eligible for any clinical trials?
• If I am premenopausal, should we discuss fertility preservation now?

• Am I a candidate for lumpectomy, or do you recommend mastectomy? Why?
• If mastectomy, what are my reconstruction options?
• How will the lymph nodes be evaluated?
• How many breast cancer surgeries do you perform per year?
• What should I expect for recovery and return to normal activities?

• What systemic treatment do you recommend, and why this specific regimen for my subtype?
• What is the expected benefit of each component of my treatment plan?
• What side effects should I expect, and how will we manage them?
• How will we monitor whether treatment is working?
• Am I a candidate for CDK4/6 inhibitor therapy? PARP inhibitor therapy? Immunotherapy?
• How long will treatment last?
• What about long-term endocrine therapy — how long, and how do we manage side effects?

• Honestly, given my specific stage and tumor biology, what is the realistic range of outcomes?
• What have you seen patients do that actually makes a difference beyond treatment?
• What is the follow-up plan after treatment ends?
• Should I get a second opinion?
• How do I reach the team between visits if something comes up?

If it is hard to find the words, these are ready to read directly to your team. Pick the ones that fit your situation.

• Ask: "What is my exact subtype — HR+/HER2-, HER2+, HER2-low, or triple-negative — and how did that come from my ER, PR, and HER2 results?"
• Ask: "Is my HER2 reported as an exact score of 0, 1+, 2+, or 3+, and could I be HER2-low or HER2-ultralow and eligible for trastuzumab deruxtecan?"
• Ask your oncologist: "Should I have germline BRCA and multi-gene panel testing, and would a result change my surgery or unlock a PARP inhibitor?"
• Ask your oncologist: "Will an Oncotype DX or MammaPrint score decide whether I need chemotherapy, and when will we have it?"
• Ask: "Is treatment before surgery (neoadjuvant) right for my subtype, and what response are you hoping to see?"
• Ask your surgeon: "Am I a candidate for lumpectomy, and can I meet a plastic surgeon before we decide on mastectomy or reconstruction?"
• Ask your oncologist: "Am I a candidate for an adjuvant CDK4/6 inhibitor such as abemaciclib or ribociclib, and what is the expected benefit for my risk level?"
• Ask: "If I am premenopausal, can I see a fertility specialist before treatment starts?"
• Ask: "How often will my heart function be checked on HER2-targeted therapy, and what result would make you pause it?"
• Ask: "What symptoms of lung inflammation should make me call you immediately if I am on Enhertu?"
• Ask your oncologist: "How long do you recommend endocrine therapy, and how will we manage side effects so I can finish it?"
• Ask: "Is there a clinical trial that fits my subtype and stage right now?"
• Ask your team: "Can I get a second opinion at a specialized breast center without delaying my care?"
• Ask: "Given my specific stage and tumor biology, what is the realistic range of outcomes?"

• The treating center’s financial counseling office. At Huntsman Cancer Institute, a patient financial advocate is assigned to new patients (801-587-7000). They help with insurance navigation, copay assistance, and payment plans.
• The oncology social worker. Most cancer centers have social workers who connect families to assistance programs.

Breast cancer drug costs fall into two very different tiers. Ask your financial counselor to map each drug on your specific plan before treatment starts.

• Endocrine (hormone) pills are inexpensive generics. With a discount coupon, generic anastrozole runs about $10 for a 30-day supply, letrozole about $13, and tamoxifen roughly $17–$20 (GoodRx cash-price estimates, July 2026). These are among the most cost-effective cancer drugs that exist.
• Targeted and antibody drugs are expensive brand-name products. The CDK4/6 inhibitors carry list prices near $16,000–$17,300 per month — palbociclib (Ibrance) about $16,500 per 28-day supply, ribociclib (Kisqali) about $16,300, and abemaciclib (Verzenio) with a list price that can exceed $17,300 per month (manufacturer list / GoodRx, July 2026). Trastuzumab deruxtecan (Enhertu) averages roughly $16,930 per prescription (about one 3-week cycle), and the PARP inhibitor olaparib (Lynparza) runs about $8,700 for a one-month supply.

The coverage path that brings these down:

• Manufacturer copay cards can reduce out-of-pocket cost to as little as $0 per month for commercially insured patients — for example the Verzenio Savings Card (up to $10,600 per year), Pfizer Oncology Together (Ibrance), the Kisqali copay program (Novartis), and AstraZeneca Access 360 (Lynparza, Enhertu). These cards cannot be used by patients on Medicare or Medicaid.
• Independent foundation grants (PAN Foundation, HealthWell Foundation, Patient Advocate Foundation Co-Pay Relief — see the assistance lists below) help Medicare patients who cannot use manufacturer cards.
• Start with the treating center’s financial counselor, who can enroll you in the right program and confirm your plan’s coverage before the first dose.

• Susan G. Komen — financial assistance, helpline, education. 1-877-465-6636. komen.org
• Living Beyond Breast Cancer (LBBC) — education, support, helpline. 888-753-5222. lbbc.org
• Breastcancer.org — comprehensive patient community and information. breastcancer.org
• Young Survival Coalition — resources for women diagnosed under 40. youngsurvival.org
• Metastatic Breast Cancer Network (MBCN) — mbcn.org
• Triple Negative Breast Cancer Foundation — tnbcfoundation.org
• SHARE Cancer Support — peer support, helpline. 844-275-7427. sharecancersupport.org

• Patient Advocate Foundation — copay relief, case management. 800-532-5274. patientadvocate.org
• CancerCare — financial-assistance grants, counseling. 800-813-4673. cancercare.org
• HealthWell Foundation — copay assistance for specific drugs. 800-675-8416. healthwellfoundation.org
• PAN Foundation — copay assistance. 866-316-7263. panfoundation.org
• NeedyMeds — prescription-assistance database. 800-503-6897. needymeds.org
• Family Reach — emergency financial help. familyreach.org

• Social Security Disability Insurance (SSDI) — 800-772-1213. ssa.gov. Breast cancer with distant metastases qualifies for expedited Compassionate Allowances.
• Medicare — 800-633-4227. medicare.gov
• Medicaid (Utah) — medicaid.utah.gov; 1-866-435-7414. The Breast and Cervical Cancer Prevention and Treatment Act provides Medicaid coverage for uninsured women diagnosed through the CDC screening program.
• FMLA — job-protected leave for patients and family caregivers; apply through employer.
• American Cancer Society — Hope Lodge lodging, 24/7 helpline. 800-227-2345. cancer.org
• Mercy Medical Angels — transportation assistance. mercymedical.org

The FDA has approved the broadest range of breast cancer agents. Key approvals include all three CDK4/6 inhibitors (palbociclib, ribociclib, abemaciclib), multiple HER2-targeted agents (trastuzumab, pertuzumab, T-DM1, T-DXd, tucatinib, neratinib, margetuximab), pembrolizumab for TNBC, sacituzumab govitecan, olaparib and talazoparib for BRCA-mutated disease, alpelisib and capivasertib for PIK3CA/AKT pathway-altered HR+ disease, and elacestrant for ESR1-mutated disease. NCCN Guidelines are the primary clinical reference.

The EMA has approved most of the same agents as the FDA, though timing may differ. CDK4/6 inhibitors, HER2-targeted therapies, and PARP inhibitors are broadly available. T-DXd received EMA approval for HER2+ and HER2-low indications. ESMO guidelines may differ from NCCN in specific recommendations. In the UK, NICE technology appraisals determine NHS funding; the Cancer Drugs Fund provides interim access to some agents. St. Gallen consensus statements are also widely referenced in Europe.

Health Canada has approved most major breast cancer agents. Provincial formulary coverage varies. The pan-Canadian Oncology Drug Review (pCODR) issues funding recommendations. Some newer agents may face delays between federal approval and provincial reimbursement. Patients can ask about special access programs. Canadian guidelines generally align with NCCN and St. Gallen.

Japan: The PMDA has approved most standard breast cancer agents. Japan has contributed significantly to breast cancer trials. The Japanese Breast Cancer Society guidelines are the primary local reference.

Australia: The TGA approves drugs, and the PBS determines subsidized access. Most major breast cancer agents are available. The Cancer Australia clinical guidance and eviQ protocols are local references.

Multiple biosimilars of trastuzumab are now available worldwide, providing more affordable access to this critical HER2-targeted therapy. These have been rigorously tested and are considered equivalent to the originator drug. The availability of trastuzumab biosimilars has significantly improved global access to HER2-directed therapy.

• Adjuvant therapy — treatment given after surgery to destroy residual microscopic cancer and reduce recurrence risk.
• Antibody-drug conjugate (ADC) — a targeted drug that combines an antibody (which finds cancer cells) with a potent chemotherapy payload (which kills them). Examples: T-DM1, T-DXd, sacituzumab govitecan.
• Aromatase inhibitor (AI) — drugs (letrozole, anastrozole, exemestane) that block estrogen production in postmenopausal women. Cornerstone of HR+ breast cancer treatment.
• Axillary lymph nodes — lymph nodes in the armpit; the first place breast cancer typically spreads.
• BRCA1 / BRCA2 — genes whose inherited mutations significantly increase breast and ovarian cancer risk. Also guide treatment with PARP inhibitors.
• CDK4/6 inhibitors — drugs (palbociclib, ribociclib, abemaciclib) that block proteins driving cancer cell division. Used with endocrine therapy in HR+ breast cancer.
• Core needle biopsy — using a hollow needle to extract tissue samples for diagnosis. Preferred over fine-needle aspiration for breast cancer diagnosis.
• DCIS — ductal carcinoma in situ; abnormal cells confined within the milk duct, not yet invasive.
• Endocrine therapy — hormone-blocking treatment for HR+ breast cancer (tamoxifen, aromatase inhibitors, ovarian suppression).
• ER (estrogen receptor) — protein on cancer cells that binds estrogen. ER-positive cancers are fueled by estrogen and respond to endocrine therapy.

• HER2 — human epidermal growth factor receptor 2; a protein that, when overexpressed, drives cancer growth. Targetable with multiple drugs.
• HER2-low — tumors with low but detectable HER2 expression (IHC 1+ or IHC 2+/ISH-negative). Now targetable with T-DXd.
• Immunotherapy — drugs that activate the immune system against cancer. In breast cancer, primarily pembrolizumab for TNBC.
• Ki-67 — a marker of how actively cancer cells are dividing. Higher values indicate more aggressive growth.
• Lumpectomy — breast-conserving surgery that removes the tumor with a margin of normal tissue.
• Lymphedema — chronic arm swelling caused by damage to lymphatic drainage from surgery or radiation.
• Mastectomy — surgical removal of the entire breast.
• Metastasis — cancer spread to distant organs (most commonly bone, liver, lungs, brain in breast cancer).
• Neoadjuvant therapy — treatment given before surgery.

• Oncotype DX — a 21-gene genomic assay that predicts recurrence risk and chemotherapy benefit in HR+/HER2- early breast cancer.
• Ovarian function suppression (OFS) — medical suppression of ovarian estrogen production using GnRH agonists in premenopausal women.
• Palliative care — specialized care for symptom relief and quality of life; runs alongside active treatment; not hospice.
• PARP inhibitor — drugs (olaparib, talazoparib) that exploit DNA repair deficiencies in BRCA-mutated cancers.
• Pathologic complete response (pCR) — no cancer remaining in the breast and lymph nodes at surgery after neoadjuvant therapy. A strong positive prognostic sign.
• PD-L1 — a protein that helps cancer evade the immune system; its expression level guides immunotherapy decisions in TNBC.
• PR (progesterone receptor) — protein on cancer cells that binds progesterone. PR-positive cancers typically co-occur with ER-positive status.
• Sentinel lymph node biopsy (SLNB) — removing only the first one to three lymph nodes draining the tumor to check for cancer spread.
• T-DXd (trastuzumab deruxtecan, Enhertu) — an antibody-drug conjugate targeting HER2; active in HER2+ and HER2-low breast cancer.
• Tamoxifen — a selective estrogen receptor modulator; blocks estrogen’s effect on breast cells. Used in pre- and postmenopausal women.
• Triple-negative breast cancer (TNBC) — lacks ER, PR, and HER2 expression. Treated primarily with chemotherapy, immunotherapy, and PARP inhibitors (if BRCA-mutated).
• Tumor board — a meeting where specialists from multiple disciplines discuss an individual patient’s case together.

Doses below are the standard adult doses stated in each drug's FDA label / prescribing information. They are provided so you can recognize your regimen — never adjust a dose yourself.

Endocrine (hormone) therapy

CDK4/6 inhibitors and HR+ targeted agents

HER2-targeted agents

Triple-negative, immunotherapy, ADCs, and PARP inhibitors

Supportive doses your team may add: to protect bone, calcium 1200 mg and vitamin D up to 2000 IU daily; for CDK4/6-related loose stools, loperamide 4 mg then 2 mg after each loose stool. CDK4/6 inhibitors act in synergy with endocrine therapy — the combination benefit is substantially greater than either alone, which is why they are given together rather than in sequence. Ask your oncologist: "What number would make you hold or stop this drug, and what symptoms should send me to the emergency room?"

How to read these numbers. The figures below are approximate 2026 United States list prices (wholesale acquisition cost) or GoodRx cash estimates. Prices change frequently and vary by dose, body weight, and region; most insured patients pay far less through insurance, copay cards, and foundation grants. Treat these as order-of-magnitude only, and confirm your real cost with your financial navigator before treatment.

Bringing the cost down. Manufacturer copay cards can cut the out-of-pocket cost of the oral targeted drugs to as little as $0 per month for commercially insured patients (for example the Verzenio Savings Card, up to $10,600 per year). These cards cannot be used by patients on Medicare or Medicaid, who instead rely on independent foundation grants (PAN Foundation, HealthWell Foundation, Patient Advocate Foundation Co-Pay Relief). Ask your oncologist: "Can your financial navigator enroll me in a copay card or foundation grant before my first dose?"

Each row lists a practice-changing trial, its ClinicalTrials.gov identifier (which you can look up directly), and the year of the related FDA approval. These are the trials that established the treatments in this guide.

These approvals rest on FDA labels, NCCN and ESMO guidelines, and the primary trial publications; your team can tell you which apply to your specific case.

Guidelines:

• NCCN Clinical Practice Guidelines — Breast Cancer (current version)
• ESMO Clinical Practice Guidelines for early and metastatic breast cancer
• St. Gallen International Expert Consensus for early breast cancer
• ASCO Clinical Practice Guidelines for breast cancer

Landmark trials referenced in this guide:

2026 approvals:

• VERITAC-2: vepdegestrant in ESR1-mutated ER+/HER2- advanced breast cancer (NCT05654623)
• DESTINY-Breast11: neoadjuvant trastuzumab deruxtecan in HER2+ early breast cancer (NCT05113251)

• PubMed (pubmed.ncbi.nlm.nih.gov) — Free public database of medical research
• ClinicalTrials.gov (clinicaltrials.gov) — Official U.S. registry of clinical trials
• NCCN Guidelines for Patients (nccn.org/patientresources) — Free patient-friendly breast cancer guidelines
• National Cancer Institute (cancer.gov/types/breast) — Comprehensive information and trial search (1-800-4-CANCER)
• Breastcancer.org — breastcancer.org
• Susan G. Komen — komen.org, 1-877-465-6636
• Living Beyond Breast Cancer — lbbc.org, 888-753-5222
• American Cancer Society — cancer.org, 800-227-2345